Mnuchin told CNBC that he's confident President Donald Trump and President Xi Jinping can make progress in stalled trade talks.World Economyread more
President Donald Trump's administration hopes additional sanctions on Iran will force the country to negotiate.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Some 4 million people have fled the South American country since 2015 amid an economic meltdown.World Politicsread more
Japanese designer Undercover posted on its Instagram account a photo of protesters with the slogan "no extradition to China," the Financial Times reported.China Politicsread more
President Trump announced fresh sanctions on the Islamic Republic on Monday, following the downing of an unmanned American drone last week.Politicsread more
Shares of Sage Therapeutics soared 70 percent on Thursday after the company announced positive results in the testing a major depressive disorder (MDD) treatment.
Sage said in a release that 64 percent of patients achieved MDD remission using the SAGE-217 drug in the 15th day of treatment.
This is the second successful drug trial result in as many months for Sage. On Nov. 9, the company said brexanolone — a drug aimed at treating moderate and severe postpartum depression — met its main goal in two late-stage studies. The stock shot up 54.2 percent that day and is up 44.1 percent over the past month.
"These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue," CEO Jeff Jonas said in a statement. "The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development."